Results 11 to 20 of about 29,725 (304)

Stimulation of Eryptosis by Caspofungin [PDF]

Cellular Physiology and Biochemistry, 2016
Background/Aims: The echinocandin antifungal agent caspofungin has been shown to trigger apoptosis of fungal cells. Beyond that, caspofungin is toxic for host mitochondria.
Thomas Peter, Rosi Bissinger, Florian Lang   +2 more
doaj   +4 more sources

Nonstationary Pharmacokinetics of Caspofungin in ICU Patients [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Standard dosing of caspofungin in critically ill patients has been reported to result in lower drug exposure, which can lead to subtherapeutic 24-h area under the curve to MIC (AUC0–24/MIC) ratios.
Agnieszka Borsuk-De Moor, Justyna Sysiak-Sławecka, E. Rypulak, M. Borys, P. Piwowarczyk, G. Raszewski, D. Onichimowski, M. Czuczwar, P. Wiczling   +8 more
semanticscholar   +5 more sources

Caspofungin [PDF]

Clinical Infectious Diseases, 2003
Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and ...
Louis D. Saravolatz, Stanley C. Deresinski, David A. Stevens   +2 more
openalex   +3 more sources

Caspofungin acetate: An antifungal agent [PDF]

American Journal of Health-System Pharmacy, 2001
The pharmacology, bioavailability and pharmacokinetics, clinical efficacy, and adverse effects of caspofungin acetate are reviewed. Caspofungin acetate is an echinocandin with fungicidal activity against a wide range of pathogens, including Candida spp., Aspergillus spp., and Histoplasma spp.

openalex   +4 more sources

Caspofungin Combined With TMP/SMZ in Treatment of Intractable Acute <i>Pneumocystis jirovecii</i> Pneumonia in Renal Transplant Recipients: Case Report and Literature Review. [PDF]

Clin Case Rep
ABSTRACT Pneumocystis jirovecii pneumonia (PJP) is a potential life‐threatening opportunistic infection that predominantly affects immunocompromised individuals, such as those with human immunodeficiency virus or organ transplant recipients. The treatment of PJP, particularly severe cases, remains challenging, as standardized treatment therapies often ...
Hu H, Xu S, Jiang W, Xu B, Wang J, Xu G.
europepmc   +2 more sources

In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method

International Journal of Infectious Diseases, 2022
Objectives: Increased resistance of Candida species, especially Candida. glabrata is problematic. Combination antifungal therapies were studied to solve the problem.
Qianting Yang, Zhiyong Liu, Yan Wang, Jiao Xie, Kanghuai Zhang, Yalin Dong, Yun F. Wang   +6 more
doaj   +1 more source

Rezafungin Utilisation in Real Life-FungiScope Results From Europe and the United States. [PDF]

Mycoses
ABSTRACT Background Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Reinhold I, Mori G, Lanzafame M, Limongelli A, Vena A, Götz J, Bauernfeind S, Hanses F, Tometten L, Mayer M, Rieke A, Soriano-Martin A, Valerio M, Vazquez JA, Yue P, Rahimli L, Azimli N, Sal E, Salmanton-García J, Vasenda N, Sprute R, Stemler J, Wingen-Heimann S, Cornely OA, Seidel D.   +24 more
europepmc   +2 more sources

Evaluation of a Novel FKS1 R1354H Mutation Associated with Caspofungin Resistance in Candida auris Using the CRISPR-Cas9 System

Journal of Fungi, 2023
Outbreaks of invasive infections, with high mortality rates, caused by multidrug-resistant Candida auris have been reported worldwide. Although hotspot mutations in FKS1 are an established cause of echinocandin resistance, the actual contribution of ...
Maiko Kiyohara, T. Miyazaki, Michiyo Okamoto, T. Hirayama, K. Makimura, H. Chibana, Nana Nakada, Y. Ito, Makoto Sumiyoshi, N. Ashizawa, K. Takeda, N. Iwanaga, T. Takazono, K. Izumikawa, K. Yanagihara, S. Kohno, H. Mukae   +16 more
semanticscholar   +1 more source

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi

bioRxiv, 2022
Current treatment of fungal infections is threatened by emerging antifungal drug resistance. In this work, the authors explore the synergistic activity of a host defense peptide mimetic, brilacidin, with caspofungin against a panel of fungal strains ...
Thaila Fernanda dos Reis, Patrícia Alves de Castro, R. W. Bastos, C. Pinzan, P. F. Souza, S. Ackloo, M. A. Hossain, D. Drewry, Sondus Alkhazraji, A. Ibrahim, Hyunil Jo, W. DeGrado, G. Goldman   +12 more
semanticscholar   +1 more source

Hsp90 governs dispersion and drug resistance of fungal biofilms [PDF]

, 2011
Fungal biofilms are a major cause of human mortality and are recalcitrant to most treatments due to intrinsic drug resistance. These complex communities of multiple cell types form on indwelling medical devices and their eradication often requires ...
A Lupetti, A Viudes, C d'Enfert, CA Kumamoto, CJ Nobile, CJ Nobile, D Andes, D Shahinas, David Andes, E Mowat, EM Kojic, ET Burt, G Ramage, G Ramage, G Ramage, G Ramage, G Ramage, Gordon Ramage, J McCourtie, J Nett, J Trepel, JB Anderson, JC Young, JE Nett, Jeniel Nett, Jose L. Lopez-Ribot, JR Blankenship, JS Finkel, L Ostrosky-Zeichner, LE Cowen, LE Cowen, LE Cowen, LE Cowen, LE Cowen, Leah E. Cowen, LH Pearl, LS Wilson, M Taipale, MA Pfaller, MA Pfaller, MJ Seidler, ML Richard, MM McNeil, Nicole Robbins, P Perumal, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, P Uppuluri, PK Mukherjee, Priya Uppuluri, R Pallavi, Ranjith Rajendran, Robin Charles May, RS Shapiro, RS Shapiro, S Garcia-Sanchez, S Park, S Perea, SD Singh, SJ Lin, SL LaFayette, SM Noble, SV Balashov, SZ Usmani, TE Zaoutis, Y Kaneko, YS Kim, Z Odabasi   +69 more
core   +22 more sources